Afamelanotide: Melanocortin MC1 receptor agonist photoprotective agent

Drugs of the Future

Volumn 35, Issue 5, 2010, Pages 365-372

  Minder, Elisabeth I ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; CUV 1647; ETP 1647; MELANIN; NDP MSH; PLACEBO; SCENESSE; STEROID; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHROPOIETIC PROTOPORPHYRIA; GENE MUTATION; HEADACHE; HUMAN; KIDNEY TRANSPLANTATION; MELANOCYTE; MELANOMA; NAUSEA; NONHUMAN; PHOTODERMATOSIS; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; QUALITY OF LIFE; SKIN DISEASE; SKIN PIGMENTATION; SOLAR URTICARIA; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; SUNLIGHT; URTICARIA;

EID: 77955465689     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.05.1484387     Document Type: Article

References (76)

1. Sawyer, T.K., Sanfilippo, P.J., Hruby, V.J., Engel, M.H., Heward, C.B., Burnett, J.B., Hadley, M.E. 4-Norleucine, 7-D-phenyl-alanine-alpha-melanocyte- stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 1980, 77(10): 5754-8.
2. Hadley, M.E., Hruby, V.J., Sawyer, T.K., Heward, C.B. (University Patents, Inc.). Synthetic analogues of alpha-melanotropin. US 4457864.
3. El Ghissassi, F., Baan, R., Straif, K. et al. A review of human carcinogens - Part D: Radiation. Lancet Oncol 2009, 10(8): 751-2.
4. Miyamura, Y., Coelho, S.G., Wolber, R. et al. Regulation of human skin pigmentation and responses to ultraviolet radiation. Pigment Cell Res 2007, 20(1): 2-13.
5. Nordlund, J.J., Boissy, R.E., Haering, V.J., King, R.A., Oetting, W.S., Ortonne, J.P. The Pigmentary System: Physiology and Pathophysiology, 2nd Ed. Malden, Massachusetts: Blackwell Publishing Ltd., 2006.
6. Barsh, G., Attardi, L.D. A healthy tan? N Engl J Med 2007, 356(21): 2208-10.
7. Prota, G. Melanins, melanogenesis and melanocytes: Looking at their functional significance from the chemist's viewpoint. Pigment Cell Res 2000, 13(4): 283-93.
8. Meredith, P., Sarna, T. The physical and chemical propenies of eumelanin. Pigment Cell Res 2006, 19(6): 572-94.
9. Chedekel, M.R., Smith, S.K., Post, P.W., Pokora, A., Vessell, D.L. Photodestruction of pheomelanin: Role of oxygen. Proc Natl Acad Sci U S A 1978, 75(11): 5395-9.
10. Gilchrest, B.A., Park, H.Y., Eller, M.S., Yaar, M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol 1996, 63(1): 1-10.
11. Lin, J.Y., Fisher, D.E. Melanocyte biology and skin pigmentation. Nature 2007, 445(7130): 843-50.
12. Abdel-Malek, Z.A., Knittel, J., Kadekaro, A.L., Swope, V.B., Starner, R. The melanocortin 1 receptor and the UV response of human melanocytes - A shift in paradigm. Photochem Photobiol 2008, 84(2): 501-8.
13. Cui, R., Widlund, H.R., Feige, E. et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007, 128(5): 853-64.
14. Thody, A.J. alpha-MSH and the regulation of melanocyte function. Ann N Y Acad Sci 1999, 885: 217-29.
15. Khated, M., Larribere, L., Bille, K., Ortonne, J.P., Ballotti, R., Bertolotto, C. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. J Invest Dermatol 2003, 121(4): 831-6.
16. Khaled, M., Larribere, L., Bille, K., Aberdam, E., Ortonne, J.-P., Ballotti, R., Bertolotto, C. Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem 2002, 277(37): 33690-7.
17. Song, X., Mosby, N., Yang, J., Xu, A., Abdel-Malek, Z., Kadekaro, A.L. alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res 2009, 22(6): 809-18.
18. Kadekaro, A.L., Kavanagh, R., Kanto, H. et al. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005, 65(10): 4292-9.
19. Kokot, A., Metze, D., Mouchet, N., Galibert, M.D., Schiller, M., Luger, T.A., Böhm, M. Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology 2009, 150(7): 3197-206.
20. Kollias, N., Baqer, A.H. Absorption mechanisms of human melanin in the visible, 400-720 nm. J Invest Dermatol 1987, 89(4): 384-8.
21. O'Donohue, T.L., Dorsa, D.M. The opiomelanotropinergic neuronal and endocrine systems. Peptides 1982, 3(3): 353-95.
22. Bertolini, A., Tacchi, R., Vergoni, A.V. Brain effects of melanocortins. Pharmacol Res 2009, 59(1): 13-47.
23. Vaidyanathan, G., Zalutsky, M.R. Fluorine-18-labeled [Nle4,D-Phe7]-alpha- MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol 1997, 24(2): 171-8.
24. Bohm, M., Luger, T.A., Tobin, D.J., Garcia-Borron, J.C. Melanocortin receptor ligands: New horizons for skin biology and clinical dermatology. J Invest Dermatol 2006, 126(9): 1966-75.
25. Roth, C.L., Enriori, P.J., Gebhardt, U. et al. Changes of peripheral alpha-melanocyte-stimulating hormone in childhood obesity. Metabolism 2010, 59(2): 186-94.
26. Schneider-Yin, X., Gouya, L., Meier-Weinand, A., Deybach, J.C., Minder, E.I. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 2000, 159(10): 719-25.
27. Lecha, M., Puy, H., Deybach, J.C. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4: 19.
28. Minder, E.I., Schneider-Yin, X., Steurer, J., Bachmann, L.M. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009, 55(1): 84-97.
29. Gouya, L., Martin-Schmitt, C., Robreau, A.M. et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006, 78(1): 2-14.
30. Wang, K.K., Lutzke, L., Borkenhagen, L. et al. Photodynamic therapy for Barrett's esophagus: Does light still have a role? Endoscopy 2008, 40(12): 1021-5.
31. Honigsmann, H. Polymorphous light eruption. Photodermatol Photoimmunol Photomed 2008, 24(3): 155-61.
32. Botto, N.C., Warshaw, E.M. Solar urticaria. J Am Acad Dermatol 2008, 59(6): 909-20.
33. Roewert-Huber, J., Stockfleth, E., Kerl, H. Pathology and pathobiology of actinic (solar) keratosis - An update. Br J Dermatol 2007, 157(Suppl. 2): 18-20.
34. Gloster, H.M. Jr., Neal, K. Skin cancer in skin of color. J Am Acad Dermatol 2006, 55(5): 741-60.
35. Brenner, M., Hearing, V.J. The protective role of melanin against UV damage in human skin. Photochem Photobiol 2008, 84(3): 539-49.
36. Vatve, M., Ortonne, J.P., Birch-Machin, M.A., Gupta, G. Management of field change in actinic keratosis. Br J Dermatol 2007, 157(Suppl. 2): 21-4.
37. Lerner, A.B., McGuire, J.S. Effect of alpha- and beta melanocyte stimulating hormones on the skin colour of man. Nature 1961, 189: 176-9.
38. Hadley, M.E., Dorr, R.T. Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization. Peptides 2006, 27(4): 921-30.
39. Sawyer, T.K., Castrucci, A.M., Staples, D.J., Affholter, J.A., De Vaux, A., Hruby, V.J., Hadley, M.E. Structure-activity relationships of [Nle4, D-Phe7]alpha-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann N Y Acad Sci 1993, 680: 597-9.
40. Andersson, P.M., Boman, A., Seifert, E., Skottner, A., Lundstedt, T. Ligands to the melanocortin receptors. Expert Opin Ther Patents 2001, 11(10): 1583-92.
41. Valverde, P., Healy, E., Jackson, I., Rees, J.L., Thody, A.J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995, 11(3): 328-30.
42. Valverde, P., Healy, E., Sikkink, S. et al. The Asp84Glu variant of the melanoconin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996, 5(10): 1663-6.
43. Bastiaens, M.T., ter Huurne, J.A., Kielich, C. et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001, 68(4): 884-94.
44. Kennedy, C., ter Huurne, J., Berkhout, M. et al. Melanoconin 1 receptor (MOR) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001, 117(2): 294-300.
45. Sturm, R.A. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res 2002, 12(5): 405-16.
46. Frandberg, P.A., Muceniece, R., Prusis, P., Wikberg, J., Chhajlani, V. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Biochem Biophys Res Commun 1994, 202(3): 1266-71.
47. Yang, Y., Dickinson, C., Haskell-Luevano, C., Gantz, I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997, 272(37): 23000-10.
48. Fitzgerald, L.M., Fryer, J.L., Dwyer, T., Humphrey, S.M. Effect of melanotan, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006, 27(2): 388-94.
49. Ugwu, S.O., Blanchard, J., Dorr, R.T. et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997, 18(3): 259-69.
50. Harms, J.H., Lautenschlager, S., Minder, C.E., Minder, E.I. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009, 85(6): 1434-9.
51. Barnetson, R.S., Ooi, T.K., Zhuang, L. et al. [Nle4-D-Phe7]-alpha- Melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006, 126(8): 1869-78.
52. Osawa, M., Egawa, G., Mak, S.S. et al. Molecular characterization of melanocyte stem cells in their niche. Development 2005, 132(24): 5589-99.
53. Fang, D., Nguyen, T.K., Leishear, K. et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65(20): 9328-37.
54. Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., Beermann, F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005, 65(10): 4005-11.
55. Frank, N.Y., Margaryan, A., Huang, Y. et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65(10): 4320-33.
56. Jiang, J., Sharma, S.D., Nakamura, S. et al. The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995, 8(6): 314-23.
57. Ghanem, G., Lienard, D., Hanson, P., Lejeune, F., Fruhling, J. Increased serum alpha-melanocyte stimulating hormone (alpha-MSH) in human malignant melanoma. Eur J Cancer Clin Oncol 1986, 22(4): 535-6.
58. Ghanem, G., Verstegen, J., Libert, A., Arnould, R., Lejeune, F. Alpha-melanocyte-stimulating hormone immunoreactivity in human melanoma metastases extracts. Pigment Cell Res 1989, 2(6): 519-23.
59. Crombie, I.K. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 1979, 40(5): 774-81.
60. MacKie, R.M., Bray, C.A., Hole, D.J. et al. Incidence of and survival from malignant melanoma in Scotland: An epidemiological study. Lancet 2002, 360(9333): 587-91.
61. Swope, V.B., Medrano, E.E., Smalara, D., Abdel-Malek, Z.A. Long-term proliferation of human melanocytes is supported by the physiologic mitogens alpha-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp Cell Res 1995, 217(2): 453-9.
62. Gehlsen, K.R., Hadley, M.E., Levine, N., Ray, C.G., Hendrix, M.J. Effects of a melanotropic peptide on melanoma cell growth, metastasis, and invasion. Pigment Cell Res 1992, 5(5, Pt. 1): 219-23.
63. Evans-Brown, M., Dawson, R.T., Chandler, M., McVeigh, J. Use of melanotan I and II in the general population. BMJ 2009, 338: b566.
64. del Marmot, V., Luger, T., Neumann, N.J., Ortonne, J.P. Public health issues arising from sale of illegal and potentially unsafe 'tanning chemicals'. Pigment Cell Melanoma Res 2009, 22(5): 648.
65. Cardones, A.R., Grichnik, J.M. α-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol 2009, 145(4): 441-4.
66. Cousen, P., Colver, G., Helbling, I. Eruptive melanocyte naevi following melanotan injection. Br J Dermatol 2009, 161(3): 707-8.
67. Langan, E.A., Ramlogan, D., Jamieson, L.A., Rhodes, L.E. Change in moles linked to use of unlicensed "sun tan jab". BMJ 2009, 338: b277.
68. Ellis, R.A., Kirkham, N., Seukeran, D. Malignant melanoma in a user of melanotan I. Br Med J 2009; http://www.bmj.com/cgi/eletters/338/feb17-2/ b566#209418.
69. Levine, N., Sheftel, S.N., Eytan, T. et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA 1991, 266(19): 2730-6.
70. Clinuvel successfully meets endpoints in phase II trial (EP012) on polymorphous light eruption. Clinuvel Pharmaceuticals Ltd. Announcement, August 28, 2006.
71. Harms, J., Lautenschlager, S., Minder, C.E., Minder, E.I. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009, 360(3): 306-7.
72. Clinuvel announces positive results in phase II solar urticaria study. Clinuvel Pharmaceuticals Ltd. Announcement, July 16, 2009.
73. Clinuvel Pharmaceuticals Limited. Afamelanotide improved quality of life in cancer patients. Clinuvel Pharmaceuticals Ltd. Announcement, December 9, 2009.
74. Minder, E.I., Harms, J., Lautenschlager, S., Schneider-Yin, X., Deybach, J.C., Minder, C.E. A double-blind, randomized, controlled phase III trial of afamelanotide (an alpha-MSH analogue) in erythropoietic protoporphyria (EPP) - Preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP. Berzelius Symp 81- Porphyrins and Porphyrias (June 14-18, Stockholm) 2009, Abst.
75. Preliminary results in Clinuvel's phase III porphyria trial. Clinuvel Pharmaceuticals Ltd. Announcement, December 21, 2009.
76. Clinuvel anounces PLE phase III preliminary results. Clinuvel Pharmaceuticals Ltd. Announcement, December 18, 2009.